Popular Articles

Statins Can Protect Against Alzheimer's Disease, According To New Study
High cholesterol levels are considered to be a risk factor not only for cardiovascular disease including stroke, but also for the development of Alzheimer"s disease. Therefore, many cholesterol lowering drugs, including statins, have been developed in recent years. In addition to the cholesterol reducing effect of statins Amalia Dolga, PhD, of the University of Groningen, The Netherlands, and her co-investigators have demonstrated that statins can protect nerve cells against damage which we know to occur in the brain of Alzheimer"s disease patients. The results are published in the June issue of the Journal of Alzheimer"s Disease.
new payday loan lenders
For DNA Analysis, Aluminum-Oxide Nanopore Beats Other Materials
Fast and affordable genome sequencing has moved a step closer with a new solid-state nanopore sensor being developed by researchers at the University of Illinois.
News of the day
Blogs Comment On 'Common Ground' Bill, Abortion Coverage In Health Reform Legislation, Other Topics
The following summarizes selected women"s health-related blog entries.~ "Democratic Bill Could Be a Preview of Obama"s Abortion Plan," Dan Gilgoff, U.S. News & World Report"s "God and Country": A recently introduced bill aimed at reducing the need for abortion is "big news because moderate to liberal faith-based advocates are urging the White House to adopt the bill ... as the core of its forthcoming "common ground" plan on abortion and reproductive health," Gilgoff writes. Some conservative religious groups, including the Southern Baptist Convention and the U.S. Conference of Catholic Bishops, "have warned the White House" that the bill is a "deal breaker" for them because of its support for comprehensive sex education and contraception, he writes. The White House "has refused to say which way it"s leaning," Gilgoff writes, adding the Obama administration could "buck" the groups that support the bill and "get behind" the Pregnant Women Support Act, "which is generally considered more robust on reducing demand for abortions and which leaves out contraceptive funding." However, he concludes, "that would be a pretty big surprise" (Gilgoff, "God and Country," U.S. News & World Report, 7/23).~ "New Report: Abortion Providers = American Human Rights Defenders, Now Under Increasing Attack," Jodi Jacobson, RH Reality Check: A new Center for Reproductive Rights report "calls on both the federal and state governments to address the growing threats against and stigmatization and abuse of abortion providers throughout the United States," Jacobson writes. The report "focuses on a key obstacle to the realization of women"s reproductive rights ... and recognizes their work as human rights defenders," she writes, adding that the U.S. has "historically been a leader both in creating and in encouraging accountability to human rights principles throughout the world." However, "[a]ccess to reproductive health care generally and abortion care specifically are basic human rights largely ignored within the context of U.S. domestic politics," Jacobson writes, noting that abortion access in the U.S. "has been increasingly limited due to the range of obstacles created through anti-choice advocacy." The report highlights several "types of rights violations [that] are most pervasive in limiting women"s choices and the rights of abortion providers," including "intimidation and harassment," "stigma" and "legal restrictions." The report makes a "series of recommendations for change at the state and local level for changes in policy and in law enforcement practices, as well as for the federal government, medical community and non-governmental organizations," Jacobson concludes, adding that the report "makes a special plea for the United Nations Special Rapporteur to document violations of women"s human rights in the United States" (Jacobson, RH Reality Check, 7/22).~ "Sixteen Governors Call on Congress To Include Medicaid Family Planning State Option in Health Reform," Jodi Jacobson, RH Reality Check: "Sixteen governors have written a letter to both Senate and House Leadership "expressing strong support for the Medicaid Family Planning State Option,"" which is included in President Obama"s fiscal year 2010 budget proposal, Jacobson writes. The governors wrote, "Many of our states have created family planning expansion programs, though we have done so with great difficulty," adding, "Since the early 1990s, 27 states have been granted federal waivers to expand their Medicaid family planning coverage. These demonstration projects have been unqualified successes, providing care to millions of women while saving states [millions] of dollars." Jacobson continues, "The current Medicaid waiver process, however, "puts unnecessary roadblocks in the way of our efforts to maintain and expand coverage for family planning services,"" according to the governors. She adds, "Passing this law as part of health care reform "would give us the needed flexibility to quickly and efficiently expand cove
Health Insurance

Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells

Researchers at the Malaghan Institute of Medical Research in Wellington, New Zealand have found that abnormally proliferating human T-cells, rapidly dividing cancer cells such as primary myeloid and lymphoid leukemic blast cells undergo programmed cell death when exposed briefly to the investigational anti-tumor drug phenoxodiol. These results make phenoxodiol a promising candidate for the treatment of pathologically activated lymphocytes such as those in acute lymphoid leukemia, or diseases driven by T-cell proliferation such as autoimmune diseases and graft-versus-host disease, according to an article published in the Haematologica Journal on June 16, 2009, http://www.haematologica.org/cgi/reprint/94/7/928. The researchers demonstrated that phenoxodiol inhibited plasma membrane electron transport and cell proliferation and promoted apoptosis of rapidly proliferating human T-cells, induced to undergo rapid proliferation by exposure to cells from an incompatible donor, but at the same time it did not affect normal resting T-cells. "These findings indicate that phenoxodiol may have utility against autoimmune diseases, such as rheumatoid arthritis and psoriasis, as well as having potential in management of graft rejection in transplantation patients," said Prof. Alan Husband, Group Director of Research, Marshall Edwards, Inc. "We"re appreciative of Dr. Patries Herst and colleagues for undertaking this important research." About phenoxodiol Phenoxodiol is being developed by the U.S. oncology company Marshall Edwards, Inc. (NASDAQ: MSHL) as a chemosensitizing agent in combination with platinum drugs for late stage, chemoresistant ovarian cancer and as a monotherapy for prostate and cervical cancers. It has a unique mechanism of action, binding to cancer cells via a surface oxidase, disrupting membrane electron transport and causing major downstream disturbances in expression of proteins necessary for cancer cell survival and responsible for the development of drug resistance. In cancer cells, phenoxodiol appears to inhibit selectively the pro-survival regulator known as S-1-P (sphingosine-1-phosphate) that is overexpressed in cancer cells. In response to phenoxodiol, the S-1-P content in cancer cells is decreased, rendering those cells more sensitive to chemotherapy. Indeed, in laboratory studies, it has been demonstrated that cancer cells pre-treated with phenoxodiol were killed with lower doses of chemotherapy drugs. Importantly, phenoxodiol has been shown not to affect adversely normal cells in animal and laboratory testing. Phenoxodiol is being investigated as a therapy for late-stage, chemoresistant ovarian, prostate and cervical cancers. Phenoxodiol has received Fast Track status from the FDA to facilitate its development as a therapy for recurrent ovarian and prostate cancers. Phenoxodiol is an investigational drug and, as such, is not commercially available. Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by FDA as being safe and effective for the intended use. Phenoxodiol is the first of a family of compounds in the Marshall Edwards, Inc. drug pipeline of flavonoid derivatives. Marshall Edwards, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):